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Abstract Novel imaging techniques using biomarkers have
clarified the mechanisms of hitherto unanswered or misunder-
stood phenomena of coronary artery disease and enabled eval-
uation of myocardial blood and tissue fluid flows in vivo.
Dye-staining coronary angioscopy using Evans blue (EB) as
the biomarker can visualize fibrin and damaged endothelial
cells, revealing that the so-called platelet thrombus is frequent-
ly a fibrin-rich thrombus; occlusive transparent fibrin throm-
bus, but not platelet thrombus, is not infrequently a cause of
acute coronary syndrome; Bfluffy^ coronary luminal surface is
caused by fibrin threads arising from damaged endothelial
cells and is a residue of an occlusive thrombus after autolysis
in patients with acute coronary syndrome without angiograph-
ically demonstrable coronary stenosis; and web or membrane-
like fibrin thrombus is a cause of stent edge restenosis. Fluo-
rescent angioscopy using visual or near-infrared light wave-
lengths is now used clinically for molecular imaging of the
substances such as lipoproteins and cholesterol that constitute
coronary plaques. Dye-staining cardioscopy using EB or fluo-
rescein enables direct and real-time visualization of subendo-
cardial microcirculation.
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Abbreviations
AS Angioscopy
ACS Acute coronary syndrome
CCD Chilled charged device
CS Cardioscopy
EB Evans blue
MTFF Myocardial tissue fluid flow
SMBF Subendocardial myocardial blood flow
Introduction
Conventional coronary angioscopy (AS) is more useful for the
evaluation of coronary plaque and thrombus than angiogra-
phy, and cardioscopy (CS) is more useful for detecting intra-
cardiac thrombi and myocardial diseases than ventriculogra-
phy. However, both imaging modalities use visible light and
both are limited to evaluating surfacemorphology and color of
the target lesions, so it is beyond the scope of either to evaluate
the composition of the target lesions. Coronary AS or CS
using biocompatible markers is one choice for evaluation of
the tissues, cells, or molecules that comprise the target lesions.
Evans blue (EB) is a blue dye used clinically for the mea-
surement of cardiac output many years ago. Beneficial effects
of this dye in preventing coronary restenosis have been report-
ed [1, 2]. Histological examinations in animals and patients
have revealed that EB stains fibrin and damaged vascular
endothelial cells (ECs) [3].
In 1995, dye-staining AS was established and was used
clinically to observe the peripheral arteries using EB as a bio-
marker for imaging fibrin and damaged ECs [4]. Further, this
imaging technique was used to evaluate coronary, pulmonary,
and aortic lesions in patients [5–7].
Furthermore, fluorescent coronary AS is now employed
clinically for molecular imaging of the substances that consti-
tute coronary plaques.
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Dye-staining CS was established for evaluation of myocar-
dial microcirculation [8–10].
Because these imaging techniques have been performed
mainly in our laboratories, our imaging techniques and obtain-
ed findings are described here.
Dye-Staining Coronary AS
Coronary AS System and Its Manipulation
The novel AS system comprises a light source (CTV-A,
Olympus Corporation, Tokyo, Japan), an angioscope of the
monorail type (VecMover, Clinical Supply Co., Gifu, Japan),
and a color chilled charged device (CCD) camera (CSVEC-
10, Clinical Supply) (Fig. 1) [11].
After coronary angiography, the angioscope is introduced
into the targeted coronary artery. The balloon of the
angioscope is inflated to stop the blood flow therein, and the
fiberscope incorporated into the angioscope is slowly ad-
vanced up to 7 cm distally to facilitate successive observations
of the artery while displacing the blood by infusion of hepa-
rinized saline solution (10 IU/mL) at a rate of 2 mL/s for 10–
20 s through the flash channel of the angioscope. To accurate-
ly confirm the location of the angioscope tip (and accordingly
the observed portion), the angioscopic and fluoroscopic im-
ages are displayed simultaneously on a monitor.
After the control observation, 1 mL of 2.5 % EB solution is
injected during balloon inflation into the artery through the
flush channel of the angioscope to stain damaged endothelial
cells or fibrin, and then, the balloon is deflated to restore blood
flow. At 1–2 min later, the balloon is re-inflated and the cor-
onary luminal surface is observed by AS [12].
Imaging of Coronary EC Damage Caused by Catheter
Manipulation
Coronary ECs protect the vascular wall against spasm and
thrombus formation through release of vasodilating and anti-
thrombotic substances. When the ECs are damaged, thrombus
immediately forms on that site [3]. However, it has been dif-
ficult to visualize damaged ECs in vivo.
Using dye-staining AS, damaged coronary ECs can be vi-
sualized, and it has become clear that cell damage is caused by
insertion of a catheter for percutaneous intervention or balloon
inflation and even by insertion of a guidewire (Fig. 2) [3, 13].
Discrimination of Coronary Fibrin and Platelets in Patients
with Acute Coronary Syndrome
Platelet thrombi play a key role in the genesis of acute coro-
nary syndrome (ACS), and it has been generally considered
that white thrombus is platelet thrombus [3]. Using dye-
staining coronary AS and EB as a marker of fibrin to examine
whether white coronary thrombus in patients with ACS is
composed of platelets alone, it was revealed that the majority
of white thrombi (so-called platelet thrombi) can be clearly
discriminated into fibrin-rich and platelet-rich thrombi
(Fig. 3) [12]. Therefore, the use of this imaging modality
may contribute to selection of effective primary or adjunctive
thrombolytic therapy.
Identification of Platelet Thrombus
To date, there has not been an established imaging method to
identify platelet thrombus in patients. My group found that
fluorescein stains both fibrin and platelets (unpublished obser-
vation), so administering fluorescein after staining fibrin with
EB may contribute to identification of platelet thrombus.
After confirming the existence of a thrombus in the culprit
coronary segment in patients with ACS, EB is injected into the
coronary artery. Next, 1 mL of 1 % solution of fluorescein is
injected into the same artery, and the fluorescence is imaged
with a fluorescent AS system using a band-pass filter of
470 nm and band-absorption filter of 515 nm. Details are
described elsewhere [11].
Following fluorescein injection, the white portion of the
thrombus, which does not stain with EB, exhibits fluores-
cence, indicating that it consists of platelets (Fig. 4).
Angiographically Obstructed but Angioscopically
Unobstructed Culprit Coronary Segment in Patients with ACS
Figure 5 shows a patient with unstable angina (UA) in whom
the left anterior descending artery was totally occluded ac-
cording to angiography. However, a residual lumen was ob-
served and nothing was seen in the lumen by conventional
AS. Dye-staining AS exposed a blue structure occupying the
residual lumen, indicating a fibrin thrombus causing total oc-
clusion. Such transparent fibrin thrombi, namely a structure
that is not visible with conventional AS and becomes visible
with dye-staining AS, have been observed in patients with UA
Fig. 1 Monorail-type angioscope for coronary use. a Balloon. b
Fiberscope. c Guidewire. Reproduced from ref. [3], with permission
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or non-ST elevation myocardial infarction (non-STEMI) but
not in those with STEMI [14•].
Detection of Damaged ECs on Coronary Stent Struts
in the Chronic Phase
Coronary in-stent thrombosis is not infrequently observed by
AS, even 6 months or more after stenting, despite the use of
ticlopidine and aspirin. However, the mechanisms underlying
late thrombosis are not well understood. ECs are highly anti-
thrombotic, so it is possible that the mechanism is damage of
the neo-ECs covering the stent struts.
Angioscopic observation of the coronary segments
6 months after bare stent implantation was performed in 44
patients. Stent struts were classified by conventional AS into
subgroups: not covered by neointima (naked group); visible
through the neointima (see-through group); and not visible
through the neointima (not-see-through group). EC damage
visualized with EB was observed in 13.3 % of the not-see-
through group and in 80 % of the see-through/naked group.
The neo-ECs covering stent struts in the see-through/naked
group stained blue with EB more frequently than in the not-
see-through group, indicating neo-EC damage (Fig. 6), which
was classified as localized or diffuse damage. Late stent
thrombosis was observed in the latter type. In animals, late
stent thrombosis occurs when the neointimal thickness is within
100 μm. Neo-ECs may be damaged by friction between them
and the stent struts, because of a thin interposed neointima, which
should act as a cushion, resulting in late stent thrombosis [15, 16].
These findings suggest the necessity of an appropriate thickness
Fig. 2 Visualization of coronary endothelial cell damage induced by
catheter manipulation. A Conventional angioscopic image of a coronary
segment after single introduction of a guidewire (arrowhead). A-1 After
injection of Evans blue (EB), linear endothelial cell damage caused by the
guidewire (arrows) can be seen. B Conventional angioscopic image of a
coronary segment after balloon inflation of an angioscope. Arrowhead:
guidewire. B-1 Dye-staining angioscopic image of the same portion.
Arrow: circumscribed staining with EB, indicating balloon-induced
endothelial cell damage. C Conventional angioscopic image of a
coronary segment proximal to the target lesion treated by stent
deployment. Arrowhead: guidewire. C-1 After EB injection, the entire
luminal surface stains blue, indicating extensive endothelial cell damage
(arrow). Arrowhead: guidewire. Reproduced from ref. [3], with
permission
Fig. 3 Discrimination of fibrin from platelets in coronary thrombi. A
White coronary thrombi (arrows) in a patient with ST-elevation
myocardial infarction. A-1 After injection of Evans blue (EB), the area
stained blue (white arrow) indicates the presence of fibrin, and the
unstained area (black arrow) indicates platelet aggregates. B Brown
mass (arrow) in the obstructed coronary segment in a patient with ST-
elevation myocardial infarction. Arrowhead: guidewire. B-1 The mass
stained blue with EB, indicating a mixture of fibrin and plaque debris
(arrow). Arrowhead: guidewire. Reproduced from ref. [12], with
permission
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of neointima for prevention of late stent thrombosis. A similar
mechanism may cause late stent thrombosis in patients in whom
a drug-eluting stent is implanted.
Fluffy Coronary Luminal Surface without Significant
Stenosis or Obstructive Thrombus in Patients with ACS
There are a considerable number of patients with ACS in
whom no significant coronary obstruction is angiographically
demonstrable. Hitherto, coronary spasm or accidental throm-
bosis has been considered as the underlying mechanism but
without definite evidence. My group noticed a certain group
of patients with ACS in whom significant stenosis is not de-
monstrable, and the suspect culprit coronary segment exhibits
a Bfluffy^ (or frosted glass-like) surface. In a few of these
patients, a thrombus distal to the fluffy segment is detected.
The fluffy surface stains blue with EB, indicating the presence
of fibrin and/or damaged ECs (Fig. 7).
Similar changes were reproduced by mechanical damage to
the artery followed by blood perfusion to produce thrombus in
dogs. Fluffy surface was exposed after removal of the globular
thrombus. Histologically, the fluffy surface was composed of
fibrin threads arising from the damaged ECs and adhered
together by platelets. Therefore, it is proposed that a coronary
segment with a fluffy or frosted glass-like surface is the site of
surface disruption, and resultant thrombosis and the changes are
related to residual fibrin and platelets after autolysis of the throm-
bus [17].
Web and Membrane Formation on the Edges of Coronary
Stents
Deployment of bare metal or drug-eluting stents into the cor-
onary artery is widely performed to treat coronary artery dis-
ease (CAD). However, it has become evident that this effec-
tive therapeutic modality brings about the occurrence of sev-
eral unwanted phenomena in patients, for instance in-stent
restenosis and subacute or late stent thrombosis.
In the course of conducting routine evaluations of im-
planted stents using coronary AS, I and my colleagues fre-
quently found band-like structures connecting two or more
stent struts, namely a web and/or membrane-like structure
connecting multiple stent struts like a curtain and obstructing
the lumen. The incidence of this phenomenon was further
investigated in the acute and chronic phases of the deployment
of stents in patients suffering from ACS and from effort
Fig. 4 Identification of platelets by fluorescent angioscopy using
fluorescein. A Brown coronary thrombus (arrow) observed by
angioscopy before injection of Evans blue (EB) in a patient with ST-
elevation myocardial infarction. A-1 The thrombus partially stained blue
with EB (arrowhead) and a white area remained (arrow). A-2 After
fluorescein injection, the white area fluoresced, indicating it comprised
platelets (arrow)
Fig. 5 Angiographically obstructed but angioscopically unobstructed
coronary segment in a patient with unstable angina. A Coronary
angiography (CAG) showing proximal segment of the left anterior
descending artery (arrow) . A-1 Angioscopic image of the
angiographically obstructed segment (arrow in A). The segment was
composed of disrupted plaque but a residual lumen existed (arrow). A-2
After injection of Evans blue (EB), the residual lumen stained blue,
indicating that it was obstructed with a transparent fibrin thrombus
(arrow). Reproduced from ref. [14•], with permission
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angina pectoris. Additional evaluation experiments were con-
ducted in animals to obtain further clarification of the mecha-
nisms entailed in this phenomenon.
Web andmembrane were observed in both patients with ACS
and those with effort angina (80.0 vs 18.7 %) immediately after
stent deployment and also 6 months later (55.5 vs 28.5 %). The
structures stained blue with EB immediately after stent deploy-
ment but not 6 months later. In beagles, the web and membrane
were observed on stent edges in 75.0 % of cases at 5 h after
stenting and in 66.6% cases at 1month later. Histological studies
revealed that the web and membrane examined 5 h after stenting
were composed of fibrin, whereas those examined 1 month later
were composed of collagen fibers (Fig. 8) [18].
The results indicated that web and membrane frequently
form on the edges of coronary stents and in the acute phase
are composed of fibrin, which is replaced by collagen fibers in
chronic phase. It is conceivable that these structures form be-
cause of blood flow turbulence and the affinity of stent struts
for platelets/fibrin.
Those findings also indicated that pretreatment with hepa-
rin is not sufficient for prevention of web and membrane
formation. Therefore, prophylactic fibrinolytic therapy just
before stent deployment may be necessary to prevent this
unwanted phenomenon.
Slow-flow phenomenon occurs in the stented coronary ar-
tery. Distal embolism and EC dysfunction have been proposed
as the main causative mechanisms of this unwanted hemody-
namic change [19]. Also, stent edge restenosis occurs in
chronic phase [20]. There is a possibility that in addition to
these mechanisms, the formation of web andmembrane on the
stent edges also contributes to the slow or no-flow phenome-
non and stent edge restenosis.
Fluorescent Angioscopy for Molecular Imaging
of Coronary Plaques
Angioscopy which enables observation of the structural
changes of the plaques and the substances which cause the
plaque vulnerable was awaited for characterization of the vul-
nerable plaques.
Recently, fluorescent angioscopy was established, and they
are now clinically used for imaging of coronary plaques.
By color fluorescent angioscopy using a band-pass filter of
345 nm and band-absorption filter of 420 nm, the yellow
plaques observed by conventional angioscopy were further
classified into three categories, namely green, white to light
blue, and yellow to orange ones, and histological examina-
tions revealed that the yellow to orange plaques lack collagen
fibers, which protect the them against disruption, indicating
that they are most susceptible to mechanical stress, namely
vulnerable [21, 22].
Oxidized low-density lipoprotein (oxLDL) and low-
density lipoprotein (LDL), which play important roles in ini-
tiation, progression, and destabilization of coronary plaques,
became visible in human coronary plaques by color fluores-
cent angioscopy using dyes as biomarkers [21, 23, 24]. Also,
triglyceride and apolipoprotein B-100, which comprise LDL,
also became visible [25]. Further, high-density lipoprotein
Fig. 6 Staining of the endothelial cells covering stent struts in the chronic
phase after stent deployment. A Stent struts can be seen through at
6 months after deployment of a Multilink stent (arrow). A-1 After
injection of Evans blue (EB), endothelial cells on the struts stained blue,
indicating cell damage (arrow)
Fig. 7 Fluffy luminal surface of culprit non-stenotic coronary segment in
a patient with acute coronary syndrome. ACoronary angiogram (CAG) of
left anterior descending artery. Arrow: Segment where fluffy luminal
surface was observed by angioscopy. A-1 Conventional angioscopy of
the same segment, showing the Bfluffy^ luminal surface like seaweed
(arrow). Arrowhead: guidewire. A-2 After injection of Evans blue (EB),
the fluffy luminal surface stained blue, suggesting the presence of fibrin
threads (arrow). Reproduced from ref. [17], with permission
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(HDL) which counteracts with oxLDL became visible (Fig. 9)
[26••, 27].
Imaging of cholesterol and cholesteryl esters, calcium, and
LDL within 700 μm in depth from the plaque surface became
visible by near-infrared fluorescent angioscopy using a band-
pass filter of 685 nm and band-absorption filter of 780 nm [28,
29].
Among these, oxLDL, HDL, cholesterol, cholesteryl es-
ters, and calcium were successfully imaged in patients with
coronary artery disease in vivo.
Fig. 8 Web-like and
membranous structures on the
edges of stent. A Coronary
angiography (CAG) immediately
after bare metal stent deployment
into the proximal segment of left
anterior descending artery.
Arrows: segment where
angioscopy was performed. B
Web-like structure on the
proximal edge of the stent
(arrow). B-1 The web stained
blue with Evans blue (EB),
indicating it was composed of
fibrin. C Membranous structure
on the distal edge of the stent
(arrow), easily displaced by a
guidewire (arrow, C-1).
Arrowhead: guidewire. C-2 The
membranous structure stained
blue with EB, indicating it was
composed of fibrin (arrow).
Reproduced from ref. [17], with
permission
Fig. 9 Imaging of HDL in human coronary plaques. Sixty-two-year-old
male. CAG coronary angiography. A Angiogram of left coronary artery
shows a slight stenosis in the proximal (arrow a) to middle segment
(arrow b) of anterior descending artery. B Conventional angioscopic
image of the portion indicated by arrow a in A shows light yellow
plaque. Arrowhead: guidewire. B-1 Color fluorescent angioscopic
(CFA) image of the same portion after administration of Fast green dye
(FG) shows diffuse brown fluorescence, indicating diffuse deposition of
HDL (arrow). BConventional angioscopic image of the portion indicated
by arrow b in A shows a yellow plaque (arrow). Arrowhead: guidewire.
C-1 CFA image of the same portion after administration of FG shows red
(arrow) fluorescence, indicating deposition of LDL and/or
lysophosphatidylcholine. Reproduced from ref [26••], with permission
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Thus, this new imaging technologies may contribute clini-
cally to clarify molecular mechanisms of coronary plaque
growth and destabilization and to evaluate the effects on them
of interventional and medical therapies.
Dye-Staining CS
Structurally, the left ventricular wall of the heart comprises
three myocardial layers, namely the inner oblique, middle
circular, and outer oblique myocardial layers [30, 31]. It is
the inner oblique layer that is most susceptible to ischemia.
Until recently, myocardial blood flow has been evaluated by
contrast echocardiography, radionuclide imaging, magnetic
resonance imaging, computed tomography, or electron beam
computed tomography. However, selective evaluation of the
blood flow in the individual myocardial layers, especially in
the inner oblique layer, namely the subendocardial myocardi-
um, is often difficult with these imaging modalities.
A CS system using white light as the light source and
obtaining color images of the heart from the inside, namely
conventional CS, was devised [32–34] and used for differen-
tial diagnosis of myocardial and valvular diseases. This imag-
ing modality also enabled observation of subendocardial myo-
cardial blood flow (SMBF). However, because endocardial
color was used as the indicator, assessment of SMBF was
greatly influenced by the intensity of the light source. There-
fore, a more reliable method for direct imaging of SMBF was
required.
As the safety of intravascular administration of EB became
evident from dye-staining AS studies, intracoronary adminis-
tration was performed in patients with CAD to observe SMBF
disturbance by CS using EB as an indicator, namely Bdye-
staining CS.^
CS System and Its Manipulation
The CS system comprises a light source (CLV-A, Olympus),
9-F guiding balloon catheter (Clinical Supply), 4.2-F
fiberscope (AF 14, Olympus), and a color CCD camera
(OTV-A, Olympus) (Fig. 10).
Patients are pretreated with oral diazepam (10 mg) before
being transferred to the catheterization laboratory. Left ven-
triculography is performed after administering 50 mg of intra-
venous lidocaine and 5,000 IU heparin. A 9-F guiding balloon
is then introduced into the left ventricle and the balloon inflat-
ed with CO2. Next, a 5-F fiberscope is advanced through the
catheter to position the fiberscope tip at the tip of the catheter.
The balloon is gently pushed against the targeted wall segment
of the left ventricle, and 50–100mL of saline solution (heparin
10 IU/mL, 37 °C) is injected through the catheter at 10mL/s to
displace the blood between the balloon and the ventricular
endocardial surface being observed. The anterior, apical, infe-
rior, and lateral walls of the left ventricle are observed. The
changes in the endocardial surface are recorded on a DVD
recorder using the color CCD camera.
After the control observation, the balloon catheter is re-
placed by a Judkins catheter, and 1 mL of 2.5 % EB is injected
into the coronary artery that irrigates the left ventricular wall
segment under study. The balloon catheter and fiberscope are
reintroduced into the left ventricle, placing the balloon cathe-
ter tip on the same wall segment that was previously observed,
and the luminal surface changes are observed again [9].
Evaluation of SMBF by Dye-Staining CS Using EB as
a Biomarker
The observed portion is the anteroapical segment in chest pain
syndrome; the wall segment that is irrigated by the artery in
which spasm is evoked by intracoronary administration of
acetylcholine in vasospastic angina (VSA); the wall segment
irrigated by the stenotic artery in angina; and the dys- or
akinetic wall segment in old myocardial infarction.
In patients without CAD, the endocardial surface diffusely
stains blue immediately after intracoronary injection of EB,
indicating normal SMBF in all patients with chest pain syn-
drome. In contrast, in patients with organic CAD, patchy
staining indicating patchy preservation of SMBF and no stain-
ing indicating absent SMBF are frequently observed. In
Fig. 10 Cardioscopy system. ACardioscope. aGuiding balloon catheter shaft. b Balloon. c Fiberscope. B Schematic of the method of observing the left
ventricular endocardial surface with the cardioscope. Ao aorta. MV mitral valve. LV left ventricle. Reproduced from ref. [3], with permission
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addition, patchy staining is also observed in patients with
VSA, a functional disease (Fig. 11).
The effects of coronary stenting on SMBF have also been
investigated, confirming restoration of SMBF by dye-staining
CS in selected patients [9].
Dye-Staining CS Using Fluorescein as a Biomarker
for Evaluation of Myocardial Tissue Fluid Flow (MTFF)
MTFF plays a critical role in maintaining the function and
survival of cardiomyocytes. The myocardial tissue fluid re-
ceives oxygen and nourishments from the coronary arterial
capillaries and conveys them to the cardiomyocytes, receiving
carbon dioxide and waste matter from the cardiomyocytes and
conveying them to the venous capillaries. Therefore, it is im-
portant to measure the MTFF, but there are no clinically avail-
able tools to measure it in vivo.
Fluorescein is used clinically to evaluate retinal vessels
[34]. Within the blood vessel, fluorescence of this dye is
masked by the corpuscles, but when separated from these,
the dye exhibits strong fluorescence [3]. When injected into
the coronary vessels, it diffuses through the microvascular
wall, separate from the blood corpuscles, into the interstitial
spaces and exhibits strong fluorescence, representing tissue
fluid flow. Therefore, if the fluorescence of this dye in the
myocardium can be visualized in vivo, a real-time evaluation
of MTFF can be attained.
My group developed a fluorescent CS system, and using
fluorescein as an indicator, the left ventricular subendocardial
MTFF was evaluated in patients with CAD. Furthermore, the
effects on MTFF of percutaneous coronary intervention or
vasodilating agents were evaluated.
Fluorescent CS System and Its Manipulation
The fluorescent cardioscopy system comprises a fluorescent
excitation unit, angioscope, guiding balloon catheter, fluores-
cent emission unit, intensified CCD (ICCD) camera, camera
controller, DVD recorder, and monitor.
The fluorescent excitation unit (CLV-A, Olympus) com-
prises a xenon lamp and a filter disc with a band-pass filter
of 470 nm for fluorescence excitation. The fluorescent emis-
sion unit (DD-2, Olympus) comprises a dichroic membrane,
which cuts the wavelength of light below 515 nm, a band-
absorption filter of 515 nm, which allows a wave length of
light more than 515 nm, an ICCD camera (C3505, Hamama-
tsu Photonics Co., Hamamatsu, Japan), and a camera control-
ler (C3510, Hamamatsu Photonics).
The cardioscope and guiding balloon catheter are the same as
those used for CS using EB. After conventional CS, the light and
image guides are connected to the excitation and emission units,
respectively. After setting the band-pass and band-absorption
filters, the light is irradiated onto the target through the band-
pass filter and light guide. The consequently evoked autofluores-
cence of the target is received by the ICCD camera through the
dichroic membrane and band-absorption filters.
After a control observation, 3 mL of 10 % fluorescein
(FluoresideR, Japan Alcon Co., Tokyo), which is clinically
used for imaging of blood flow [35], is injected into the right
femoral vein. Fluorescent images are obtained at 0.5, 1, 3, and
6 min after finishing fluorescein injection [10].
MTFF in Patients with CAD
The fluorescent images of MTFF are classified as follows:
diffuse with high intensity indicating normal MTFF; diffuse
but with low intensity indicating decreased MTFF; no fluo-
rescence indicating absent MTFF; and patchy fluorescence
indicating patchy preservation of MTFF. In a previous study,
MTFFwas normal in all 18 patients with chest pain syndrome,
patchy, decreased, or absent MTFF in 16 of 20 patients with
angina pectoris and/or old myocardial infarction from organic
CAD, and patchy in 21 of 28 patents with VSA. In 10 of 20
patients who underwent coronary stenting, the angiographic
Fig. 11 Dye-staining cardioscopy. A, A-1 Patient with chest pain
syndrome without significant coronary stenosis. A Before intracoronary
injection of Evans blue (EB), the endocardial color was brown, indicating
normal myocardial blood flow. A-1 After intracoronary EB injection, the
endocardial surface diffusely stained blue, indicating normal myocardial
blood flow (arrow). B, B-1 Patient with old myocardial infarction. B
Endocardial surface is white to yellowish brown. B-1 After
intracoronary EB injection, the endocardial surface partially stained
blue, indicating that myocardial blood flow remained in a small area
(arrow). Reproduced from ref. [9], with permission
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result was successful, but MTFF disturbance frequently
remained (Fig. 12) [10].
Conclusions
Dye-stainingAS using EB as a biomarker has clarified themech-
anisms of hitherto unanswered or misunderstood phenomena of
CAD by visualizing fibrin and damaged ECs; so-called platelet
thrombus is frequently a fibrin-rich thrombus; occlusive transpar-
ent fibrin thrombus but not platelet thrombus is not infrequently a
cause of ACS; fluffy coronary luminal surface is caused by fibrin
threads attached to spontaneously damaged ECs and is a residue
of occlusive thrombus after autolysis in patients with ACS and
without angiographically demonstrable coronary stenosis; and
web or membrane-like fibrin thrombus is a cause of stent edge
restenosis, suggesting the necessity for fibrinolytic therapy for
restenosis prevention.
Using new biomarkers, this imaging technique is now used
clinically for molecular imaging of the substances that consti-
tute atherosclerotic lesions. Dye-staining CS using EB enables
direct and real-time visualization of SMBF and therefore en-
ables determination of which coronary branch supplies collat-
eral blood flow to the observed wall segment. Fluorescent CS
using fluorescein as a biomarker enables visualization of real-
time changes in MTFF which plays a critical role in maintain-
ing the function and survival of cardiomyocytes.
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